Global Financial Private Client’s Sarepta Therapeutics SRPT Stock Holding History

Global Financial Private Client’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4	Closed	-$255	–	1400
2025 Q1	$255	Hold	4	–	–	﹤0.01%	1478
2024 Q4	$486	Hold	4	–	–	﹤0.01%	948
2024 Q3	$500	Hold	4	–	–	﹤0.01%	783
2024 Q2	$632	Hold	4	–	–	﹤0.01%	640
2024 Q1	$514	Hold	4	–	–	﹤0.01%	678
2023 Q4	$386	Hold	4	–	–	﹤0.01%	669
2023 Q3	$474	Hold	4	–	–	﹤0.01%	651
2023 Q2	$454	Hold	4	–	–	﹤0.01%	649
2023 Q1	$550	Hold	4	–	–	﹤0.01%	648
2022 Q4	$518	Hold	4	–	–	﹤0.01%	643
2022 Q3	$440	Hold	4	–	–	﹤0.01%	621
2022 Q2	$303	Hold	4	–	–	﹤0.01%	630
2022 Q1	$330	Hold	4	–	–	﹤0.01%	640
2021 Q4	$360	Hold	4	–	–	﹤0.01%	631
2021 Q3	$384	Hold	4	–	–	﹤0.01%	585
2021 Q2	$313	Hold	4	–	–	﹤0.01%	592
2021 Q1	$305	Hold	4	–	–	﹤0.01%	564
2020 Q4	$682	Buy	+4	New	+$593	﹤0.01%	514

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Global Financial Private Client's SRPT Position: Q2 2025 in Review

Global Financial Private Client sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 4 shares — an estimated $255 sold.

Global Financial Private Client first reported a position in SRPT in Q4 2020 and held it in 18 quarters. The position peaked at $682 in Q4 2020. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Global Financial Private Client reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Global Financial Private Client sold 4 Sarepta Therapeutics shares in Q2 2025, an estimated $255.
Global Financial Private Client first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 18 quarters.
Global Financial Private Client's Sarepta Therapeutics position peaked at $682 in Q4 2020.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Global Financial Private Client's 13F filing for Q2 2025, filed 10 Jul 2025.